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Background. Ureters are fundamental for keeping kidneys free from uropathogenic Escherichia coli (UPEC),
but we have shown that 2 strains ( J96 and 536) can subvert this role and reduce ureteric contractility. To deter-
mine whether this is (1) a widespread feature of UPEC, (2) exhibited only by UPEC, and (3) dependent upon
type 1 ﬁmbriae, we analyzed strains representing epidemiologically important multilocus sequence types ST131,
ST73, and ST95 and non-UPEC E. coli.
Methods. Contractility and calcium transients in intact rat ureters were compared between strains. Mannose
and ﬁm mutants were used to investigate the role of type 1 ﬁmbriae.
Results. Non-UPEC had no signiﬁcant effect on contractility, with a mean decrease after 8 hours of
8.8%, compared with 8.8% in controls. UPEC effects on contractility were strain speciﬁc, with decreases from
9.47% to 96.7%. Mannose inhibited the effects of the most potent strains (CFT073 and UTI89) but had variable
effects among other UPEC strains. Mutation and complementation studies showed that the effects of the UTI89
cystitis isolate were ﬁmH dependent.
Conclusions. We ﬁnd that (1) non-UPEC do not affect ureteric contractility, (2) impairment of contractility is
a common feature of UPEC, and (3) the mechanism varies between strains, but for the most potent UPEC type 1
ﬁmbriae are involved.
Urinary tract infections (UTIs) are the most common
laboratory-conﬁrmed infections in Europe and North
America, accounting for substantial medical costs
worldwide [1]. Most UTIs are caused by uropathogenic
Escherichia coli (UPEC). Indeed studies suggest that
80%–95% of all community-acquired infections arise
as a consequence of UPEC colonization [1, 2]. As the
ureters perform an essential function in the transpor-
tation of urine from the kidneys to the bladder, efﬁ-
cient ureteric contractility and peristalsis is vital in
preventing renal infection. Peristalsis is brought about
by propagating action potentials giving rise to global
Ca transients, which underlie waves of phasic contrac-
tions of the smooth muscle that pass down the ureteric
walls [3]. It has been shown that E. coli colonization
can impair ureteric peristalsis, which in turn potenti-
ates the infection due to urinary stasis and/or vesi-
coureteric reﬂux [4, 5]. A better understanding of the
potential impact of uropathogenic E. coli on ureteric
peristalsis may help us to understand the pathogenesis
of renal infection.
E. coli are generally classiﬁed according to their clinical
properties and carriage of virulence genes, which broadly
classiﬁes pathovars as either diarrheagenic or
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extraintestinal. Extraintestinal E. coli such as UPEC possess viru-
lence characteristics that allow them to persist in and colonize
regions outside the gastrointestinal tract.
Many factors have been implicated in the virulence of
UPEC infections, including adhesins (type 1, S/F1C, and P pili
[ﬁmbriae]) [6–8], hemolysin, autotransporter toxin, sidero-
phores, capsule, and cytotoxic necrotizing factor 1 [9, 10].
UPEC encode numerous adhesive pilus ﬁbers assembled by
the chaperone/usher pathway [11] that are often tipped with
adhesins that bind to receptors with stereochemical speciﬁcity
[12], thus facilitating colonization and bioﬁlm formation [13].
All UPEC encode the class of chaperone/usher pathway pili
known as type 1 pili that are tipped with the mannose-
binding FimH adhesin. FimH is known to bind mannosylated
proteins such as uroplakins that coat the luminal surface of
both the human and murine bladder [14]. FimH has been
shown to facilitate bacterial colonization and invasion of
human bladder cells [15]. Internalized UPEC can escape into
the host cell cytoplasm, where they are able to subvert expul-
sion and innate defenses by aggregating into bioﬁlm-like intra-
cellular bacterial communities in a FimH-dependent process
[13]. Intracellular bacterial community formation has been
documented in exfoliated bladder epithelial cells in the urine
of a small proportion of women presenting with acute uncom-
plicated urinary tract infection [16]. In agreement with these
ﬁndings and in support of a role for FimH in humans, it has
been shown that the ﬁmH gene is under positive selection in
human clinical isolates of UPEC [7].
Whole-genome sequencing has been used to identify
UPEC-associated pathogenicity islands [17–19]. There have
also been a number of studies reporting the distribution of
speciﬁc genomic regions among UPEC isolates [20–23], indi-
cating that not all E. coli isolates associated with UTI carry
UPEC-associated virulence genes. Various studies have dem-
onstrated the presence of virulence genes normally associated
with UPEC in diarrheagenic E. coli [24] and avian pathogenic
E. coli (APEC) [21, 25], suggesting that other non-UPEC
strains might have the potential to act as uropathogens. The
majority of drug-resistant UPEC causing UTI in the United
Kingdom are members of an epidemic clone of the ST131
lineage, ﬁrst reported in January 2008 [26, 27]. Isolates of the
ST131 clone are signiﬁcant contributors to UTIs and are often
associated with invasive disease and/or high-level antimicrobial
resistance [27–31]. ST131 isolates have also been recovered
from the intestines of healthy humans [32]. Other lineages of
epidemiological importance are ST73 and ST95 [31].
We have previously characterized the morphology, Ca
signals, and contractility patterns in animal [33] and human
[3] ureter tissues and have validated the rat as a good experi-
mental model for the human ureter and for the study of
UPEC infection [3, 34]. In addition, we have shown that 2
strains of UPEC isolated from human pyelonephritis patients
( J96 and 536) have an inhibitory effect on ureteric function
in both species, which is thought to be mediated by type 1
ﬁmbriae [34].
The aim of this study was to analyze epidemiologically im-
portant UPEC and a selection of non-UPEC strains in our
well-characterized live tissue model, to allow real-time monitor-
ing of ureteric smooth muscle contractility and calcium signal-
ing during exposure to bacteria. We report that the inhibitory
effect is restricted to UPEC but shows variation between strains.
In addition, we report further analysis of the role of type 1 ﬁm-
briae in the effect of UPEC on ureteric contractility.
MATERIALS AND METHODS
Bacterial Strains Used in This Study
A total of 6 UPEC, 1 APEC, 2 enteropathogenic E. coli (EPEC),
and 1 chicken gut commensal strain (Table 1) were tested along
with a relevant nonpathogenic TG2 (K-12 derivative) strain and
saline as controls. Two examples of ST131 strains from a previ-
ous survey in northwest England [31] were tested (EC958 and
M160), along with 2 examples of ST73 strains (M9 and M12).
Strain UTI89 (ST95) [19] and CFT073 (ST73) [17] were includ-
ed as well-characterized genome-sequenced UPEC strains also
representing common multilocus sequence types. Two EPEC
strains, E2348/69 [35] and D55 [36], and 1 APEC strain, 3770
(isolated from the reproductive tract of a chicken), along with a
chicken commensal strain, 5138 (isolated from chicken gut),
were also included. To investigate the role of type 1 ﬁmbriae in
mediating the observed changes in ureteric function, several ﬁm
mutants were studied. These included a full ﬁm operon deletion
mutant SJH-1106 (UTI89 Δﬁm) (Chen and Hultgren, unpub-
lished data), a ﬁmH deletion mutant SLC2-17-ﬁmH (UTI89
ΔﬁmH) [7], and a ﬁmH deletion complemented with wild-type
ﬁmH SLC2-33-1(UTI89 ΔﬁmH/pﬁmH) [7].
Preparation of Bacterial Suspensions
Suspensions of E. coli were prepared using methods estab-
lished for use in a murine model of UTI [37]. Brieﬂy, E. coli
were streaked onto Luria agar plates to obtain single colonies,
which were then used to inoculate 10 mL of Luria broth in
125-mL Erlenmeyer ﬂasks. Cultures were incubated statically
overnight at 37°C to ensure optimal type 1 pilus expression.
The following day, a 25-µL volume of each strain was subcul-
tured into 25 mL of Luria broth in a 250-mL Erlenmeyer ﬂask
and incubated overnight, as before. Following static serial
passage, cultures were pelleted at 5000 g for 5 minutes at 4°C.
The pellet was resuspended in sterile physiological saline or,
for type 1 pilus inhibition studies, in sterile physiological saline
containing 25 mM methyl α-D-mannopyranoside (MαDM),
and was diluted until the OD600 for each strain corresponded
to 1–2 × 107 colony-forming units (CFU) per 50 µL.
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Ureteric Contractility Experiments
Adult female rats (Charles River, United Kingdom) were killed
humanely by use of CO2 anesthesia followed by cervical dislo-
cation in accordance with United Kingdom legislation, and
ureters were removed and placed in physiological saline before
dissection. Ureters were cut into 1-cm lengths and loaded with
15 μM of cell permeant ﬂuorescent Ca-sensitive indicator indo-
1 AM in Pluronic F-127 (Molecular Probes/Invitrogen, Paisley,
United Kingdom) for 3.25 hours. Loaded tissues were washed
in physiological saline and injected with 2–4 × 106 CFU in
physiological saline, using a 33G needle and disposable sterile
syringe before securing the tissue ends in aluminum foil clips.
Tissues were superfused at 7–8 mL/min and 30°C (unless
stated otherwise) with buffered physiological saline (pH 7.4)
composed of 154 mM NaCl, 5.6 mM KCl, 1.2 mM MgSO4,
2 mM CaCl2, 8 mM glucose, and 10.9 mM HEPES. In some
studies, 25 mM MαDM was added as a competitive inhibitor
of type 1 pilus–mediated interactions.
For measurements of intracellular calcium, Indo-1 was used
as described elsewhere [3, 34]. Loaded ureteric preparations
were mounted on 2 stainless steel hooks, one of which was
attached to a force transducer, and stretched (passive force
being 25%–30% of the active force produced by electrical ﬁeld
stimulation to set optimal length, as spontaneous activity was
rarely seen in these preparations). Rectangular pulses of 5–7 V
and 100 ms duration were applied at 40-second intervals.
Agglutination of Saccharomyces cerevisiae
E. coli strains were assessed for their ability to aggregate yeast
cells to assess the expression of functional type 1 pili [38].
Table 1. Collated Data Showing the Percentage Inhibition of Contractile Amplitude After Exposure to Each Strain of Escherichia coli
for 8 Hours, Compared With Saline Control









EC958 (ST131) UPEC E. coli clinical isolate; UK [43] 7 78.03 < .0005 82.06 NS 1:64
M160 (ST131) UPEC E. coli clinical isolate;
Upton (unpublished)
11 75.98 < .0005 11.67 < .0005 1:128
M9 (ST73) UPEC E. coli clinical isolate; Upton
(unpublished)
5 42.18 < .0005 38.33 NS 1:128
M12 (ST73) UPEC E. coli clinical isolate; Upton
(unpublished)
5 9.47 NS 9.75 NS 1:64
UTI89 (ST95) UPEC Cystitis E. coli isolate [19] 6 96.75 < .0005 10.24 < .0005 1:1024
CFT073 (ST73) UPEC Pyelonephritis E. coli isolate
[17]
5 87.93 < .0005 9.45 < .005 1:512
2348/69 EPEC Enteropathogenic E. coli; gift
from J. N. Fletcher [35]
5 9.82 NS … … 1:16
D55 EPEC Enteropathogenic E. coli; gift
from J. N. Fletcher [36]
5 8.7 NS … … 1:16
3770 APEC Chicken isolate; gift from
P. Wigley
5 8.41 NS … … 1:512
5138 None Chicken commensal strain;
gift from P. Wigley
5 8.39 NS … … 1:32
TG2 None K-12 derivative; laboratory
control strain
7 8.67 NS … … 1:64
Control NA Physiological saline 8 8.77 … … … …
UTI89 ΔfimH UPEC Knockout of fimH in UTI89
SLC2-17-fimH [7]
5 10.24 NS … … ND
UTI89 ΔpfimH UPEC Knockout of fimH in UTI89
complemented with wt
fimH SLC2-33-1 [7]
5 43.92 < .0005 … … ND
UTI89 Δfim UPEC Full fim operon deletion SJH-
1106; Chen and Hultgren
unpublished
5 9.09 NS … … ND
Strains causing significant inhibition were also assessed in the presence of 25 mM methyl α-D-mannopyranoside (MαDM). Data are the results of 4 independent
experiments.
Abbreviations: NA, not applicable; ND, not done; NS, not significant; UPEC, uropathogenic E. coli; +, present; –, absent.
a Compared with saline control at 8 h. A P value of > .05, by an unpaired t test, is statistically significant.
b Compared with −MαDM at 8 h. A P value of > .05, by an unpaired t test, is statistically significant.
c Agglutination titers of Saccharomyces cerevisiae in the presence and absence of 3% w/v MαDM are shown for each strain of E. coli.
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Yeast agglutination assays were performed as described by Li
et al [39]. Brieﬂy, static overnight cultures of E. coli were
washed by repeated centrifugation in phosphate-buffered saline
and resuspended to an OD600 of 1. Commercial baker’s yeast
(S. cerevisiae) suspensions (1% w/v) containing 0.01% (w/v)
Brilliant Blue R-250 were prepared in sterile phosphate-buffered
saline with or without 3% (w/v) MαDM. Serial dilutions of bac-
terial suspensions were made in V-bottomed 96-well plates
(1:2) and mixed with an equal volume of yeast suspension.
After 1 hour at room temperature, the agglutination titer was
determined as the last dilution yielding positive aggregations.
Unless otherwise stated, all stock salts and buffers were pur-
chased from Sigma-Aldrich (Dorset, United Kingdom).
Statistics
A sample size of 5 animals per strain was calculated using
GraphPad StatMate with estimates SD based on previously
published data from similar control and treatment groups in
the same animal model [34]. All results were expressed as
means ± standard error (SE), and data were analyzed for statis-
tical difference with an unpaired t test, with signiﬁcance taken
when P < .05. Unless stated otherwise, “n” represents observa-
tions on different animals.
RESULTS
Effects of E . coli Strains in the Intact Rat Ureter Model
Phasic contractions were evoked in rat ureters by electrical
ﬁeld stimulation, and changes in phasic activity and calcium
transients were studied over time following inoculation with
4 × 106 CFU E. coli. Figure 1 shows representative mean data
that demonstrate the time-dependent decrease in amplitude of
phasic contractions that occurred over time with E. coli strains
exhibiting high (CFT073 [ST73]), intermediate (M9 [ST73]),
and low (3770 [APEC]) inhibitory activity, when compared to
initial amplitude (taken for 100%).
Data summarizing the effect of all E. coli strains tested on
ureteric contractility are given in Table 1. Both ST131 UPEC
strains EC958 and M160 produced signiﬁcant time-dependent
inhibition of phasic contractions, reducing their amplitude
after 8 hours of exposure to 22% ± 1.6% and 24% ± 9.7% of
control, respectively. No signiﬁcant difference in contractile
amplitude was observed after 8 hours in ureters inoculated
with nonpathogenic TG2 (91.3% ± 3.2% of initial amplitude),
compared with those containing physiological saline alone
(91.2% ± 3.2% of initial amplitude).
Figure 1 shows mean data recorded from ureters exposed
lumenally to ST73 isolate M9, which caused a 42.2% ± 7.3%
fall in the amplitude of phasic contractions after 8 hours of
exposure (Table 1). However, no signiﬁcant deterioration of
ureteric contractility was seen in samples exposed to ST73
strain M12, (90.5% ± 2.3% of initial amplitude), when com-
pared to TG2 and physiological saline.
Of all the UPEC isolates tested, CFT073 (ST73) and UTI89
(ST95) produced the most aggressive response, restricting ure-
teric activity to small, nonpropagating contractions after 8
hours of exposure (12.1% ± 6.3% and 3.3% ± 4.7% of initial
amplitude for CFT073 [ST73] and UTI89 [ST95], respectively).
Figure 1 shows the typical functional deterioration observed in
ureters exposed to CFT073 (ST73) over time.
Typical traces of phasic activity and calcium transients re-
corded during exposure to CFT073 (ST73), demonstrated that
the loss of activity is mediated by depression of the duration
and amplitude of the calcium transient that drives contractility
(Figure 2C). This effect is consistent with our previous studies
investigating the effect of well-characterized pyelonephritis
strains of E. coli J96 and 536 in intact rat ureters [34], which
showed similar mean inhibition (88.8% and 86.6% of control,
respectively).
Prolonged exposure of rat ureters to the EPEC strains 2348/
69 or D55 did not cause any signiﬁcant impairment of ureteric
contractility over an extended period of 12 hours, when
compared to physiological saline (9.8% ± 0.6%) or TG2
(8.7% ± 0.4%) nonpathogenic controls, respectively (Table 1).
Mean collated data at each time point shows that although
there was a small decrease in amplitude over time, this did not
differ signiﬁcantly from control values at the same time point
(data not shown).
Rat ureters exposed to strains 3770 and 5138 showed no
signiﬁcant impairment of contractile function over the course
of an 8-hour experiment. Representative force and calcium
traces from exposure to 3770 did not show any marked de-
crease of activity over time (Figure 2A). These strains resulted
in only 8.4% ± 0.7% and 8.4% ± 0.3% reductions in amplitude,
respectively, over the duration of exposure (Table 1). These
data are comparable with the normal average decreases
Figure 1. Effects of Escherichia coli applied to rat ureteric lumen.
Example traces of strains causing low (3770), intermediate (M9), and
high (CFT073) impairment of ureteric contractile amplitude over time.
Statistical signiﬁcance was determined by an unpaired t test (P < .0005)
is denoted by an asterisk.
1592 • JID 2012:206 (15 November) • Floyd et al
observed in control samples. Together, these data show that
neither EPEC nor APEC or chicken commensal strains caused
impairment of function or calcium signaling in an intact
tissue model of ureteric infection over 8 hours.
Effect of Mannose on UPEC Inhibition of Contractility
A dose of 25mM MαDM was able to block the inhibitory
effects of M160 (ST131; 11.7% ± 1.3%) (Figure 3) but not
EC958 (ST131; 82.1% ± 1.6%) (Table 1). In ureters exposed to
M9 (ST73), MαDM was unable to completely block the inhib-
itory effects of M9 on contractile amplitude but the onset of
ureteric impairment was delayed by 2 hours (42.2% ± 7.3 for –
MαDM, compared with 38.3% ± 3.5 for +MαDM). The inhib-
itory effects of UPEC strains UTI89 (ST95) and CFT073
(ST73), which caused the largest impairment of contractility,
were abolished in the presence of 25 mM MαDM
(10.2% ± 1.7% and 9.5% ± 2.3%, respectively).
Type 1 Fimbrial Mutants of UTI89 (ST95) Have Reduced Ability
to Inhibit Contractility
Deletion of the UTI89 (ST95) ﬁm operon eradicates its ability
to impair ureteric contractility. Rat ureters exposed to the full
ﬁm operon deletion mutant (UTI89 Δﬁm) showed only small,
statistically insigniﬁcant decreases in contractile amplitude after
8 hours of exposure (9.1% ± 0.2%) (Figure 4), when compared
to the wild-type parental UTI89 (ST95) strain, which induced a
96.8% reduction in contractile amplitude (Table 1). In addition,
no signiﬁcant change in contractile amplitude was observed in
ureters exposed lumenally to UTI89 (ST95) lacking ﬁmH
(10.2% ± 0.8%), suggesting that contractile impairment is medi-
ated in part by FimH-mediated binding of bacteria with host
urothelium. The inhibitory capacity was partially restored
(43.9% ± 5.2%) when UTI89 ΔﬁmH was complemented with
wild-type ﬁmH (UTI89 ΔﬁmH/pﬁmH) (Figure 4).
Agglutination of S. cerevisiae
The prevalence of type 1 ﬁmbriae was determined by the pres-
ence or absence of mannose-sensitive yeast agglutination
(MSYA) of S. cerevisiae (Table 1). Strains showing the greatest
impairment of contractility also demonstrated the highest
MSYA titer (1:1024 for UTI89 [ST95] and 1:512 for CFT073
[ST73]). UPEC strains that demonstrated intermediate effects
on contractile amplitude showed MSYA titers of 1:128 (M160
and M9). Surprisingly, EC598 showed a comparably low MSYA
titer (1:64) while retaining a high capacity for contractile im-
pairment. This level of MSYA was also seen in UPEC M12, a
strain that showed no statistically signiﬁcant attenuation of
ureter contractile amplitude. However, APEC 3770 demonstrat-
ed MSYA at similar levels to CFT073 (ST73) without inducing
any signiﬁcant change in contractility. MSYA was observed in
EPEC strains 2348/69 and D55, as well as in APEC 5138, at
titers of 1:16 for EPEC and 1:32 for APEC; none of these
strains showed any signiﬁcant inhibition of ureter function.
These data suggest that mannose-binding capacity does not
consistently correlate with effects on ureteric function.
DISCUSSION
These data provide the ﬁrst evidence to suggest that impaired
ureteric contractility during infection is a general feature of
UPEC but that other E. coli, such as EPEC and APEC, do not
cause a similar effect. We have also found that the strength of
Figure 2. Effects of Escherichia coli applied to rat ureteric lumen on
force and calcium transients. Example recordings of force and calcium
transients from rat ureters loaded with calcium-sensitive Indo 1 and
exposed to E. coli strains that exhibit low (A, 3770), intermediate (B,
M9), and high (C, CFT073) impairment of ureteric contractile amplitude
over time. Figures show that impaired ureter activity is mediated by a
decrease in the duration and amplitude of the calcium transient.
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the effect varies between UPEC strains and that there are
strain variations with respect to the role of type 1 ﬁmbriae.
One of our UPEC strains (M12 [ST73]) did not exhibit any
effect at all. This strain had low agglutination activity, suggest-
ing that production of type 1 ﬁmbriae is impaired. The
reasons for this are not known, but it is possible that this
strain is carrying a mutation that impacts its production of
type 1 ﬁmbriae. Differences in adhesion, even in the presence
of equivalent levels of type 1 ﬁmbriation, have previously
been reported in populations of E. coli isolated from different
host niches. Such strains displayed structural differences in
the ﬁmH gene that can impair D-mannose-sensitive
adhesion [40].
The effects on contractility mediated by UTI89 (ST95),
CFT073 (ST73), and M160 (ST131) are mannose sensitive, in-
dicating that the initial cascade of events is mediated by type 1
ﬁmbrial binding to mannose residues expressed on urothelial
cells [41]. This is supported by our studies using speciﬁc type
1 ﬁmbrial deletion mutants of strain UTI89. Small-molecular-
weight compounds that speciﬁcally inhibit the FimH type 1
pilus lectin can prevent and treat UPEC infections in an in
vivo mouse model of UTI [42]. Consequently, these com-
pounds may also reduce the ability of mannose-sensitive
UPEC, such as UTI89 (ST95), CFT073 (ST73), and M160
(ST131), to decrease contractility. However, mannose-sensitive
agglutination was not found to correlate with functional
effects on ureter contractility in all strains tested. Although
APEC 3770 produced similar levels of MSYA to CFT073
(ST73), no signiﬁcant change in contractility was observed.
Similar evidence for normal mannose-binding capacity but at-
tenuated in vivo ﬁtness of E. coli has previously been demon-
strated in UPEC UTI89 (ST95) having an A27V/V163A
double mutant in ﬁmH. The A27V/V163A mutant strain had
no effect on mannose binding in vitro. However, compared
with wild-type, this double mutant strain exhibited a 10 000-
fold reduction in mouse bladder colonization 24 hours after
inoculation and was unable to form intracellular bacterial
communities in a mouse model of UTI even though it bound
normally to mannosylated receptors in the urothelium [7].
The impaired contractility caused by exposure to EC958
(ST131) was resistant to MαDM inhibition, suggesting that
the observed ureteric dysfunction might be mediated by an al-
ternative mechanism involving other chaperone/usher
pathway adhesins, such as S, F1C, or P ﬁmbriae. Genome se-
quence analysis has shown that strain EC958 carries an inacti-
vating insertion in the ﬁmB gene, which is consistent with the
observed resistance to MαDM [43]. Relatively little is known
about the speciﬁc virulence mechanisms that make ST131
UPEC suited to causing invasive disease in humans. Studies of
virulence marker prevalence in a collection of ﬁrst nondupli-
cate isolates (n = 300) recovered from urine specimens in 2 di-
agnostic laboratories in northwest England found a low
prevalence of several UPEC-associated virulence genes [31].
Consequently, although there is signiﬁcant evidence to suggest
that toxins produced by UPEC, such as hemolysin and cyto-
toxic necrotizing factor 1, might contribute to the observed
effects on contractility [10], the absence of hlyA and cnf1
genes in EC958 suggest that the mechanism varies between
strains. Other virulence factors, such as autotransporters,
which are widely expressed in UPEC, including those in our
study [43], and include secreted autotransporter toxin (Sat)
Figure 3. Effects of methyl α-D-mannopyranoside (MαDM) on inhibi-
tion of phasic ureteric activity mediated by uropathogenic Escherichia
coli (UPEC). A, Contractile amplitude in rat ureters exposed lumenally to
UPEC M160 in the presence and absence of 25 mM MαDM is shown. B,
Example recordings of force and calcium transients from rat ureters
loaded with calcium-sensitive Indo 1 and exposed to M160 in the pres-
ence and absence of 25 mM MαDM are shown. Statistical signiﬁcance
was determined by an unpaired t test (P < .0005) is denoted by an
asterisk.
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[10], surface-located UpaH [44], and trimeric UpaG [45], may
also be important in this response in some strains.
It has been suggested that APEC might serve as a reservoir
of plasmid-mediated virulence genes transmissible to other
bacteria [21]. Given the lack of physiological evidence in our
studies for a role in affecting intact tissue preparations directly,
this would seem a more plausible role for APEC in mediating
human urinary tract disease rather than acting as a uropatho-
gen themselves. Interestingly, comparative studies of virulence
genes in 524 APEC and 200 UPEC isolates identiﬁed substan-
tial areas of overlap between the 2 groups: APEC showed a
39.1% frequency of the papG allele II, compared with 24% of
UPEC [21]. The class II papG allele is speciﬁcally associated
with human pyelonephritis and bacteremia. Conversely, the
class III papG, which is associated with human cystitis, was
only found with a low frequency in APEC (0.6% of isolates),
compared with UPEC (25.5% of isolates) [46–48]. The fre-
quency with which papG II is detected in APEC, coupled with
the almost ubiquitous expression of the ﬁmH adhesin of the
type 1 pilus (98.1% of isolates), provides evidence that certain
subgroups of APEC might harbor the ability to bind to
human urothelial cells. We found no evidence that the APEC
strain tested in this study had an effect on ureter contractility,
but it may be that there are variations among APEC strains.
Infection with UPEC strains UTI89 (ST95), CFT073
(ST73), EC958 (ST131), M160 (ST131), and M9 (ST73) signif-
icantly depressed normal phasic activity in rat ureters within 5
hours, with some strains completely abolishing activity after 8
hours. The delayed onset of contractility impairment is consis-
tent with current understanding that the initial phase of infec-
tion involves colonization and invasion of urothelial cells 1–3
hours after inoculation [49]. The changes in contractility were
found to result from reductions in the intracellular calcium
transients that underlie force production, as clearly seen in
Figures 2 and 3. Thus, irrespective of the different virulence
mechanism, a reduction in calcium signaling is the common
ﬁnal pathway [50]. This study, coupled with our previous
studies, demonstrates that this experimental animal model
provides a good representation of events occurring in human
ureter tissues during the initial stages of infection [34]. Our
study indicates that an ability to impact on ureteric contractil-
ity is a widespread feature of UPEC but that the mechanisms
involved may vary between strains.
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